Dr. Jamie Chaft, MD – New York, NY

Overview of Dr. Chaft

Dr. Jamie Chaft is an oncologist in New York, NY and is affiliated with multiple hospitals in the area, including Memorial Sloan-Kettering Cancer Center and Memorial Sloan Kettering Monmouth. She received her medical degree from New York University Grossman School of Medicine and has been in practice 11 years. Dr. Chaft accepts several types of health insurance, listed below. She is one of 468 doctors at Memorial Sloan-Kettering Cancer Center and one of 14 doctors at Memorial Sloan Kettering Monmouth who specialize in Oncology. She has more than 100 publications and over 500 citings.

Education & Training

• Memorial Sloan Kettering Cancer CenterFellowship, Hematology and Medical Oncology, 2009 - 2012

• New York Presbyterian Hospital (Cornell Campus)Residency, Internal Medicine, 2006 - 2009

• New York University School of MedicineClass of 2006

Certifications & Licensure

• FL State Medical License 2021 - Present

• NY State Medical License 2008 - 2025

• NJ State Medical License 2017 - 2025

• NC State Medical License 2020 - 2022

• American Board of Internal Medicine Medical Oncology

Clinical Trials

Publications & Presentations

PubMed

• Induction Therapy for Non-Small Cell Lung Cancer.

  Cooper, A., Chaft, J., Bott, M.> ;The Journal of Thoracic and Cardiovascular Surgery. 2024 Feb 12

• The Emerging Role of Immunotherapy in Resectable Non-Small Cell Lung Cancer.

  Dunne, E., Fick, C., Isbell, J., Chaft, J., Altorki, N., Park, B., Spicer, J., Forde, P., Gomez, D., Iyengar, P., Harpole, D., Stinchcombe, T., Liberman, M., Bott, M.,...> ;The Annals of Thoracic Surgery. 2024 Feb 3
• 1 citations

  Initial Chemotherapy for Locally Advanced and Metastatic NUT Carcinoma.

  Luo, J., Sanchez, M., Lee, E., Hertzler, H., Luong, N., Mazzola, E., Finstein, B., Tamen, R., Brisbane, G., Nguyen, T., Paik, P., Chaft, J., Cheng, M., Khalil, H., Pih...> ;Journal of Thoracic Oncology. 2023 Dec 27
• Join now to see all

Journal Articles

• Effect of Osimertinib and Bevacizumab on Progression-Free Survival for Patients with Metastatic EGFR-Mutant Lung Cancers  

  Helena A Yu, Adam J Schoenfeld, Jamie E Chaft, Gregory J Riely, JAMA Oncology

• Differential Regulation of PD-L1 Expression by Immune and Tumor Cells in NSCLC and the Response to Treatment with Atezolizumab (Anti–PD-L1)  

  Alan Sandler, David S Shames, Hartmut Koeppen, Jamie Chaft, Scott N Gettinger, Alexander Spira, Daniel S Chen, Naiyer A Rizvi, David R Spigel, Proceedings of the National Academy of Sciences

• Pathologic Features of Response to Neoadjuvant Anti-PD-1 in Resected Non-Small Cell Lung Carcinoma: A Proposal for Quantitative Immune-Related Pathologic Response Crit...  

  J M Isbell, N Rekhtman, J D Wolchok, J E Chaft, Annals of Oncology
• Join now to see all

Lectures

• Randomized phase II study of adjuvant afatinib for three months versus two years in patients with resected stage I-III EGFR mutant NSCLC. 

  2019 ASCO Annual Meeting - 6/1/2019

• EA5142 adjuvant nivolumab in resected lung cancers (ANVIL). 

  2018 ASCO Annual Meeting - Chicago, Illinois - 06/3/2018

Press Mentions

• Moving the Goal Posts for Pre-Op and Post-Op Chemotherapy for Resectable NSCLCJuly 8th, 2022

• Clinical Challenges: Small Cell Lung CancerNovember 15th, 2019

• Cisplatin-Based Chemo: Still on Track in NSCLCSeptember 7th, 2019

• Join now to see all

Hospital Affiliations

Insurance Accepted